ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases
04 déc. 2019 00h45 HE
|
ImCheck Therapeutics SAS
-- Bpifrance and Pfizer Ventures co-led international investor syndicate -- Marseille, France, December 04, 2019, 6:45 AM CET – ImCheck Therapeutics, a biotech company developing a first-in-class...
ImCheck Therapeutics appoints Paul Frohna MD, PhD, PharmD,as Chief Medical Officer
20 juil. 2019 11h00 HE
|
ImCheck Therapeutics SAS
Paul Frohna brings over 15 years of experience in translational medicine and clinical and regulatory strategy Marseille, France, 18 July 2019 – ImCheck Therapeutics, a biotech company on the cutting...
ImCheck Therapeutics lève 20 M€ et recrute son Président
02 mai 2017 11h59 HE
|
ImCheck Therapeutics SAS
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
ImCheck Therapeutics lève 20 M€ et...
ImCheck Therapeutics raises €20 Million and appoints its CEO
02 mai 2017 11h59 HE
|
ImCheck Therapeutics SAS
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
ImCheck Therapeutics raises €20...